杜薇
中国医学科学院阜外医院 介入医学科
BACKGROUND:Some microRNAs have been found to be abnormal in patients with acute cerebral infarction (ACI) after intravenous thrombolysis. This study aimed to measure the expression of miR-106a-5p in ACI patients before and after thrombolytic treatment, and to investigate the prognostic value of miR-106a-5p and computed tomography perfusion imaging (CTPI) parameters in ACI patients receiving thrombolysis.METHODS:The levels of serum miR-106a-5p were detected by quantitative real-time PCR in 78 ACI patients before thrombolysis, 24 hours after thrombolysis, and 3 months (90 days) after onset. The correlation of miR-106a-5p with continuous variables were analyzed using Pearson correlation analysis. The association of miR-106a-5p and CTPI parameters with prognosis of patients receiving thrombolysis was evaluated by logistic regression analysis. The accuracy and thresholds of miR-106a-5p and CTPI parameters for discriminating patients with unfavorable prognosis after thrombolysis were assessed by receiver operating characteristic analysis.RESULTS:Serum miR-106a-5p expression was decreased in ACI patient after thrombolysis. Then, significant correlations of miR-106a-5p with National Institutes of Health Stroke Scale and CTPI parameters were found. Moreover, miR-106a-5p, cerebral blood flow (CBF) and cerebral blood volume (CBV), which are 2 CTPI parameters, were independently correlated with short- and long-term prognosis after thrombolysis. Furthermore, miR-106a-5p, CBF and CBV revealed good accuracy in predicting the prognosis of patients after thrombolysis, and their combination showed the best accuracy.CONCLUSION:Thrombolysis downregulates miR-106a-5p in ACI patients, and miR-106a-5p, CBF and CBV have considerable potentials to predict short- and long-term prognosis in ACI patients receiving intravenous thrombolysis.
Medicine 2023
BACKGROUND:Acute cerebral infarction (ACI) is a common cerebrovascular disease. Previous studies have shown that some abnormally expressed microRNAs (miRNAs) play important roles in ACI. This study aimed to investigate the role of miR-106a-5p in the diagnosis and prognosis of ACI patients, and analyze the regulatory potential of miR-106a-5p on the inflammation of BV-2 microglial cells.METHOD:Serum and cerebrospinal fluid (CSF) samples were collected from 98 ACI patients, and the expression of serum miR-106a-5p was analyzed using qRT-PCR. A receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of miR-106a-5p. The association of miR-106a-5p with ACI prognosis was evaluated using the logistic analysis. In vitro experiments were performed in BV-2 cells by oxygen glucose deprivation (OGD) treatment, and the effects of miR-106a-5p on BV-2 inflammation were assessed using an enzyme linked immunosorbent assay (ELISA).RESULT:It was observed that miR-106a-5p was significantly upregulated in the serum and CSF of ACI patients (all P < 0.001), and had considerable diagnostic accuracy. The highest serum miR-106a-5p was observed in severe ACI cases, and miR-106a-5p expression was significantly increased in unfavorable prognosis patients. Serum and CSF expression of miR-106a-5p was positively correlated with proinflammatory cytokines in ACI patients, and the inflammation of OGD-induced BV-2 cells was suppressed by miR-106a-5p reduction.CONCLUSION:MiR-106a-5p is overexpressed in ACI patients and may serve as a diagnostic and prognostic biomarker for ACI. Furthermore, miR-106a-5p may be involved in ACI progression by regulating neuroinflammation.
BMC neurology 2023
